Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
1 hedge funds and large institutions have $2K invested in Immune Pharmaceuticals Inc. in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 12 closing their positions.
92% less funds holding
Funds holding: 13 → 1 (-12)
99% less capital invested
Capital invested by funds: $172K → $2K (-$170K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 12
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$47K |
| 2 |
Barclays
London,
United Kingdom
|
-$35K |
| 3 |
Renaissance Technologies
New York
|
-$26K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26K |
| 5 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$16K |
IMNP Hedge Fund Activity: Q3 2018 in Review
1 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q3 2018, worth a combined $2K — down 99% from $172K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IMNP and 0 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was CVI Holdings, exiting entirely with an estimated $47K sold.
- 1 institutional investor held Immune Pharmaceuticals Inc. (IMNP) as of Q3 2018, down from 13 in Q2 2018.
- Funds reported $2K of Immune Pharmaceuticals Inc. stock for Q3 2018, down 99% quarter-over-quarter.
- 0 funds opened new Immune Pharmaceuticals Inc. positions in Q3 2018 and 12 closed out, a net change of -12 holders.
- The largest Immune Pharmaceuticals Inc. seller in Q3 2018 was CVI Holdings, an estimated $47K sold.
Based on aggregated 13F filings for Q3 2018.